Rockwell Medical Inc(RMTI)stock report

Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Finance:
Market Cap:178.4M; Shares Outstanding:64M; Short Interest: 10.43%; Q3 2019(9/30/19): Cash 29M. Loss 7.86M

EPS and Sales:
https://finance.yahoo.com/quote/RMTI/financials?p=RMTI

Date EPS % last year % last quarter
2018.12.31 -0.61 -19.61% -38.64%
2019.3.31 -0.15 -36.36% 75.41%
2019.6.30 -0.3 12.29% -100.00%
2019.9.30 -0.45 -2.27% -50.00%

 

Date Sales % last year % last quarter
2018.12.31 63.39M 10.63% 36.23%
2019.3.31 15.56M 4.09% -75.45%
2019.6.30 30.41M 1.82% 95.44%
2019.9.30 45.81M -1.55 50.64%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=RMTI&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/RMTI/institutional-ownership/

2020.01.15:
Total institutions: 111,no change
Shares hold: 14038.4k shares. no change
shares% hold: 21.95%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/RMTI/price-targe

Leave a Reply

×